Home > Publications Database > Capture of Longitudinal Change in Real-Life Walking in Cerebellar Ataxia Increases Patient Relevance and Effect Size. > print

001     280027
005     20250824001720.0
024 7 _ |a 10.1002/mds.30230
|2 doi
024 7 _ |a pmid:40395207
|2 pmid
024 7 _ |a pmc:PMC12273614
|2 pmc
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:177705759
|2 altmetric
037 _ _ |a DZNE-2025-00871
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Seemann, Jens
|b 0
245 _ _ |a Capture of Longitudinal Change in Real-Life Walking in Cerebellar Ataxia Increases Patient Relevance and Effect Size.
260 _ _ |a New York, NY
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755684661_25776
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a With disease-modifying drugs for degenerative ataxias on the horizon, ecologically valid measures of gait performance that can detect patient-relevant changes in trial-like time frames are highly warranted.In this 2-year longitudinal study, we aimed to unravel ataxic gait measures sensitive to longitudinal changes in patients' real lives using wearable sensors.We assessed longitudinal gait changes of 26 participants with degenerative cerebellar disease (Scale for the Assessment and Rating of Ataxia [SARA]: 9.4 ± 4.1) at baseline, 1-year, and 2-year follow-up using three body-worn inertial sensors in two conditions: (1) laboratory-based walking (LBW); and (2) real-life walking (RLW). In RLW, a context-sensitive analysis was performed by selecting comparable walking bouts according to macroscopic gait characteristics. Gait analysis focused on measures of spatio-temporal variability, particularly stride length variability, lateral step deviation, and a compound measure of spatial variability (SPCmp).Gait variability measures showed high test-retest reliability in both walking conditions (intraclass correlation coefficient [ICC], ≥0.82). Cross-sectional analyses revealed high correlations of gait measures with ataxia severity (SARA, effect size ρ ≥ 0.75); and with patients' subjective balance confidence (Activity-specific Balance Confidence scale [ABC]: ρ ≥ 0.71). Although SARA showed longitudinal changes only after 2 years, the gait measure SPCmp revealed changes after 1 year with high effect size (rprb = 0.80). Sample size estimation for the gait measure SPCmp showed a required cohort size of n = 42 participants (n = 38; spinocerebellar ataxias [SCA]1/2/3 subgroup) to detect a 50% reduction in progression at 1 year with a hypothetical intervention, compared to n = 147 for SARA at 2 years.Because of their ecological validity and larger effect sizes, real-life gait characteristics represent promising performance measures as outcomes for future treatment trials. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a biomarker
|2 Other
650 _ 7 |a cerebellar ataxia
|2 Other
650 _ 7 |a digital health
|2 Other
650 _ 7 |a real‐life walking
|2 Other
650 _ 7 |a wearable sensors
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Cerebellar Ataxia: physiopathology
|2 MeSH
650 _ 2 |a Cerebellar Ataxia: complications
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Walking: physiology
|2 MeSH
650 _ 2 |a Gait Analysis
|2 MeSH
650 _ 2 |a Gait Disorders, Neurologic: physiopathology
|2 MeSH
650 _ 2 |a Gait Disorders, Neurologic: etiology
|2 MeSH
650 _ 2 |a Reproducibility of Results
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Gait: physiology
|2 MeSH
700 1 _ |a Beyme, Theresa
|b 1
700 1 _ |a John, Natalie
|b 2
700 1 _ |a Harmuth, Florian
|b 3
700 1 _ |a Giese, Martin
|b 4
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 5
|u dzne
700 1 _ |a Timmann, Dagmar
|b 6
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 7
700 1 _ |a Ilg, Winfried
|0 P:(DE-2719)9001643
|b 8
773 _ _ |a 10.1002/mds.30230
|g Vol. 40, no. 7, p. 1343 - 1355
|0 PERI:(DE-600)2041249-6
|n 7
|p 1343 - 1355
|t Movement disorders
|v 40
|y 2025
|x 0885-3185
856 4 _ |u https://pub.dzne.de/record/280027/files/DZNE-2025-00871%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280027/files/DZNE-2025-00871.pdf
856 4 _ |u https://pub.dzne.de/record/280027/files/DZNE-2025-00871%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/280027/files/DZNE-2025-00871%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/280027/files/DZNE-2025-00871%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/280027/files/DZNE-2025-00871.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:280027
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811275
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
920 1 _ |0 I:(DE-2719)5000005
|k AG Schöls
|l Clinical Neurogenetics
|x 0
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000005
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21